CAMBRIDGE COMBINATORIAL SIGNS LEAD OPTIMIZATION DEAL WITH SOLVAY PHARMACEUTICALS
Cambridge, UK … Cambridge Combinatorial Ltd, a wholly owned subsidiary of Oxford Molecular Group plc (London Stock Exchange: OMG), today announced it has signed an agreement with Brussels-based Solvay Pharmaceuticals to provide chemistry services for lead optimization.
Dr Allan Marchington, Chief Executive of Cambridge Combinatorial said: "Our track record and expertise in lead optimization is built on the foundation of strong medicinal chemistry and pharmaceutical industry experience. We are very pleased that Solvay has recognised this strength and chosen to work with us."
Cambridge Combinatorial will synthesize and supply libraries of compounds to Solvay. As in all of its collaborations, the compounds supplied by Cambridge Combinatorial will be of high purity and be accompanied by comprehensive analytical data.
"Solvay has made various strategic alliances and joint ventures to keep its research productive and innovative," said Prof. Siegfried Schäfer, global research head for Solvay Pharmaceuticals. "We are very much looking forward to working with Cambridge Combinatorial on this project, and we believe their approach to chemistry will be of great potential benefit in our lead optimization programmes".
For further information, please contact:
Cambridge Combinatorial
David T Philips, Vice-President, Business Development
Tel: +44 1223 722400
HCC·De Facto Group plc
Michaela Mahon/Chris Gardner, HCC·De Facto Group plc
Tel: +44 171 496 3300
Notes to editors
Cambridge Combinatorial Limited
Cambridge Combinatorial Limited provides world-class, innovative chemistry services to
accelerate discovery and process research, servicing the pharmaceutical, agrochemical and
biotechnology industries. The Company is a wholly owned subsidiary of Oxford Molecular
Group plc.
Oxford Molecular
Oxford Molecular is a worldwide provider of information technology and drug discovery
research services to the pharmaceutical, biotechnology and chemical industries.
Headquartered in Oxford, England, the company also has operations in eight US cities as
well as sales offices and agents around the world. The company supplies desktop and
enterprise-wide software solutions that support research across the entire discovery
process, including target identification, lead identification and optimization, molecular
modeling and physico-chemical property prediction. Oxford Molecular's drug discovery
research services offer an integrated, highly cost-effective solution for accelerating
drug discovery utilizing teams of experienced pharmaceutical researchers who use
state-of-the-art technologies to develop novel targets and advanced screening
capabilities, design novel active compounds and synthesize high quality compounds using
combinatorial chemistry.
Solvay Pharmaceuticals
SOLVAY is an international chemical and pharmaceutical group, headquartered in Brussels,
present in 46 countries with more than 34,000 employees. Its consolidated sales in 1997
reached BEF 311 billion (USD 8.4 billion), generated by four sectors of activity:
Chemicals, Plastics, Processing, and Pharmaceuticals. Solvay Pharmaceuticals is an
important player in carefully selected therapeutic target areas in the fields of
psychiatry, cardiology, gastroenterology and gynaecology.